Clinical Trial Update: Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy® [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating JPB898, a nivolumab biosimilar, in combination with ipilimumab for melanoma, was terminated after an integrated PK/efficacy/safety/immu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• JPB898 (nivolumab biosimilar)
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Sandoz | Conditions: Melanoma | Phase 3 | Status: TERMINATED